Eisai Inc.Eisai Inc.

Ramzi AyyadRamzi Ayyad

Nita Silimkhan Nita Silimkhan

Sean RyanSean Ryan

Mission, Vision, ValuesMission, Vision, Values

Human Health Care (HHC) missionHuman Health Care (HHC) mission Also Florence Nightingale's signatureAlso Florence Nightingale's signature Innovative solutions for preventive careInnovative solutions for preventive care Cure and care for health and well being worldwideCure and care for health and well being worldwide

Vision: responsible, focused, efficient, innovative Vision: responsible, focused, efficient, innovative and solution-oriented pharma companyand solution-oriented pharma company..

Values: Integrity, respect, professionalism, Values: Integrity, respect, professionalism, quality,quality,

and teamwork. and teamwork.

Eisai Corporation: A Global Eisai Corporation: A Global Company Company

Founded as Nihon Eisai Co. in Japan in 1941.Founded as Nihon Eisai Co. in Japan in 1941.

Current headquarters in Tokyo JapanCurrent headquarters in Tokyo Japan

More than 9,000 employees worldwideMore than 9,000 employees worldwide

40 subsidiaries and 2 Joint Ventures worldwide.40 subsidiaries and 2 Joint Ventures worldwide. Joint Ventures:Joint Ventures:

Bracco Corporation (Italian Company), P.T. IndonesiaBracco Corporation (Italian Company), P.T. Indonesia.. Wholly Owned Subsidiaries present in 19 countries:Wholly Owned Subsidiaries present in 19 countries:

North America : U.S.A (5 sites)North America : U.S.A (5 sites) Europe: U.K., Sweden, Germany, France, Italy, Switzerland, Spain, Europe: U.K., Sweden, Germany, France, Italy, Switzerland, Spain,

NetherlandsNetherlands Asia: Japan, Indonesia, Taiwan, China, India, Malaysia, Singapore, Asia: Japan, Indonesia, Taiwan, China, India, Malaysia, Singapore,

Philippines, South Korea, ThailandPhilippines, South Korea, Thailand

Eisai Inc. of North AmericaEisai Inc. of North America

Eisai first established in the U.S. in 1981Eisai first established in the U.S. in 1981 Headquarters in Woodcliff Lake, NJ as of 2007Headquarters in Woodcliff Lake, NJ as of 2007

Chairman and CEO : Hajime ShimizuChairman and CEO : Hajime Shimizu

  President and COO : Lonnel Coats President and COO : Lonnel Coats

  VP Business Development: Alex ScottVP Business Development: Alex Scott

  VP Finance and CFO: Kenneth R (Ken) Klauser VP Finance and CFO: Kenneth R (Ken) Klauser

  VP and General Counsel: Douglas B. Snyder VP and General Counsel: Douglas B. Snyder

  VP Sales and Marketing: Frank CirielloVP Sales and Marketing: Frank Ciriello

  Research Facilities: Research Facilities: Eisai Medical Research Inc., Ridgefield NJEisai Medical Research Inc., Ridgefield NJ Eisai Research Institute of Boston, Andover, MaEisai Research Institute of Boston, Andover, Ma Eisai Inc./ RTP, Research Triangle Park, NCEisai Inc./ RTP, Research Triangle Park, NC

Other:Other: Eisai Machinery : Pharmaceutical Machinery SalesEisai Machinery : Pharmaceutical Machinery Sales

Eisai’s Alliance/Acquisitions History Eisai’s Alliance/Acquisitions History in the U.S.in the U.S.

1994 -- agreement with Pfizer Inc to co-promote Aricept® 1994 -- agreement with Pfizer Inc to co-promote Aricept®

1997 -- agreement with Janssen Pharmaceuticals Inc. to co-promote 1997 -- agreement with Janssen Pharmaceuticals Inc. to co-promote Aciphex®Aciphex®

2002 -- acquires Cerebyx from Warner Lambert company.2002 -- acquires Cerebyx from Warner Lambert company.

2003 -- agreement with Teva Pharmaceuticals to co-promote rasagiline.2003 -- agreement with Teva Pharmaceuticals to co-promote rasagiline.

2004 -- acquires anti-epileptic drug Zonegran® from Elan Corporation2004 -- acquires anti-epileptic drug Zonegran® from Elan Corporation

2006 -- acquires four oncology-related products from Ligand 2006 -- acquires four oncology-related products from Ligand Pharmaceuticals.Pharmaceuticals.

2007 –- acquires Morphotek biopharmaceutical company2007 –- acquires Morphotek biopharmaceutical company

Eisai Inc.: Inside the numbersEisai Inc.: Inside the numbers

Eisai 5 year stock performance on Eisai 5 year stock performance on NYSENYSE

Ticker Symbol: ESALYTicker Symbol: ESALY

Apr 11Apr 11thth 2008 price: $34.45 2008 price: $34.45

Traded as ADR on NYSETraded as ADR on NYSE

Osaka Securities ExchangeOsaka Securities Exchange

Tokyo Stock ExchangeTokyo Stock Exchange

Financial Highlight Financial Highlight ComparisonComparison

Eisai Pfizer WyethSales Revenue* 6.67 billion 48.42 billion 22.4 billion

Income* 6.98 million 8.21 billion 4.62 billion

Sales Growth* 12.10% 0.10% 10.10%

Income Growth 3.50% 82.10% 18.90%

Net Profit Margin* 10.50% 17.05% 20.61%

R&D expense per Revenue* 13% 16.71%1 14.5%1

Dividend and yield 1.18 (3.42%) 1.17 (6.26%) 1.12(2.49%)

Market Cap 9.79 billion 138.32 billion 60.80 billion

EPS* 2.45 1.17 3.37

Forward P/E 13.8 8.6 13.1

*Last 12 months1 FY 2007 Income Statement SOURCE: MSN SOURCE: MSN MoneyMoney

Percent Growth RatePercent Growth Rate

Growth Rates % EisaiIndustr

yS&P 500

Sales (Qtr vs year ago qtr) 8.5 39.4 16.2

Net Income (YTD vs YTD) 17.3 61.5 14.6

Net Income (Qtr vs year ago qtr) 3.5 46.2 8.6

Sales (5-Year Annual Avg.) 9.32 36.68 13.88

Net Income (5-Year Annual Avg.) 14.1 45.57 20.41

Dividends (5-Year Annual Avg.) 32.85 1.22 11.89

Source : MSN MoneySource : MSN Money

Liquidity Ratio ComparisonsLiquidity Ratio Comparisons

Financial Condition CompanyIndustr

yS&P 500

Debt/Equity Ratio 0.04 0.5 1.4

Current Ratio 2.1 3.4 1.2

Quick Ratio 1.8 3.1 0.9

Interest Coverage NA 360.9 49.3

Leverage Ratio 1.5 1.9 4.6

Book Value/Share 19.9 8.34 21.59

Source : MSN MoneySource : MSN Money

Profitability RatiosProfitability Ratios

Investment Returns % CompanyIndustr

yS&P 500

Return On Equity 13.2 7.6 25.5

Return On Assets 9.2 3 8.2

Return On Capital 12.4 5.5 10.9

Return On Equity (5-Year Avg.) 12.5 -0.9 20.8

Return On Assets (5-Year Avg.) 8.6 2.5 7.5

Return On Capital (5-Year Avg.) 11.4 2.9 10

Source : MSN MoneySource : MSN Money

Eisai Recent NewsEisai Recent News

Development of Parkinson disease drug, Perampanel (E Development of Parkinson disease drug, Perampanel (E

2007), was halted after failing late-stage drug trial2007), was halted after failing late-stage drug trial.. (Bloomberg.com)(Bloomberg.com)

Eisai won a court battle barring Teva pharmaceutical from Eisai won a court battle barring Teva pharmaceutical from selling the Alzheimer drug, Aricept, which accounts for 40% selling the Alzheimer drug, Aricept, which accounts for 40% of the company’s revenues . of the company’s revenues . (Bloomberg.com)(Bloomberg.com)

Eisia to resume clinical trial studies on E2012, an alzheimer Eisia to resume clinical trial studies on E2012, an alzheimer drug. drug. (pharmalive.com).(pharmalive.com).

FDA approved Aloxi injection for post operative nausea and FDA approved Aloxi injection for post operative nausea and vomiting vomiting (Eisai press release, 3/02/08)(Eisai press release, 3/02/08)

Eisai’s PharmaceuticalsEisai’s Pharmaceuticals

Two major moneymakersTwo major moneymakers AriceptAricept AciphexAciphex

Three othersThree others CerebryxCerebryx ZonegranZonegran FragminFragmin

AriceptAricept

improves cognition for improves cognition for Alzheimer’s disease - oralAlzheimer’s disease - oral

Sales from 75 countries Sales from 75 countries

(but not England)(but not England) Best pill on the market, Best pill on the market,

but far from a miracle pillbut far from a miracle pill Off-patent: November 2010Off-patent: November 2010

AciphexAciphex

Proton pump inhibitor, forProton pump inhibitor, for GERD (gastroesophageal GERD (gastroesophageal reflux disease) - oralreflux disease) - oral

Co-marketed with PriCara Co-marketed with PriCara (Ortho-McNeil, part of (Ortho-McNeil, part of J&J) in J&J) in U.S.; marketed as Pariet U.S.; marketed as Pariet outside outside U.S.U.S.

Also approved for treatment of ulcers Also approved for treatment of ulcers w/antibiotics (2002)w/antibiotics (2002)

Off-patent: May 2013Off-patent: May 2013

FragminFragmin

Clot-buster - injectableClot-buster - injectable Bought U.S. rights from PfizerBought U.S. rights from Pfizer Stops deep-vein thrombosisStops deep-vein thrombosis

(DVT) which can lead to (DVT) which can lead to pulmonary edema (PE)pulmonary edema (PE)

Also approved for angina Also approved for angina w/aspirinw/aspirin Low-molecular-weight heparins – general Low-molecular-weight heparins – general

heparin problems with Chinese suppliersheparin problems with Chinese suppliers

Eisai’s Seizure PortfolioEisai’s Seizure Portfolio

Cerebyx – seizure control - injectableCerebyx – seizure control - injectable

-Owned by Pfizer, marketed by Eisai -Owned by Pfizer, marketed by Eisai via hospital-based sales forcevia hospital-based sales force

Zonegran – seizure medication - oralZonegran – seizure medication - oral

-Bought from Elan-Bought from Elan

Eisai’s Oncology PortfolioEisai’s Oncology Portfolio

ONTAKONTAK Targretin (capsules)) Targretin (gel) Panretin (gel)

Eisai’s Research FocusEisai’s Research Focus

Neurology Neurology Gastrointestinal disordersGastrointestinal disorders CancerCancer Acute CareAcute Care

The Eisai Research PipelineThe Eisai Research PipelinePhase I CompoundsPhase I Compounds

E5555 – Critical care acute coronary E5555 – Critical care acute coronary syndrome syndrome

Aciphex – Gastrointestinal disorder Aciphex – Gastrointestinal disorder extended release formulationextended release formulation

E7080 – Cancer oral anti-cancer agentE7080 – Cancer oral anti-cancer agent E7974 – CancerE7974 – Cancer E7820 - CancerE7820 - Cancer

The Eisai Research PipelineThe Eisai Research PipelinePhase II CompoundsPhase II Compounds

AS-3201 – Diabetic NeuropathyAS-3201 – Diabetic Neuropathy E7389 – Cancer non small cell lung E7389 – Cancer non small cell lung

cancercancer E2007 – Neurology-migraine preventionE2007 – Neurology-migraine prevention Aciphex – Gastrointestinal disorder, Aciphex – Gastrointestinal disorder,

pediatric usepediatric use Aciphex - Gastrointestinal disorder, Aciphex - Gastrointestinal disorder,

intermittent therapy for symptomatic intermittent therapy for symptomatic gastroesophageal reflux diseasegastroesophageal reflux disease

The Eisai Research PipelineThe Eisai Research PipelinePhase II Compounds (cont.)Phase II Compounds (cont.)

E7389 – Breast cancerE7389 – Breast cancer E2007 – Neurology-epilepsyE2007 – Neurology-epilepsy E7389 – Prostate cancerE7389 – Prostate cancer

The Eisai Research PipelineThe Eisai Research PipelinePhase III/Submission to FDAPhase III/Submission to FDA

E5564 – Critical care-severe sepsisE5564 – Critical care-severe sepsis Rufinamide – epilepsyRufinamide – epilepsy Aricept – Severe Alzheimer’s disease Aricept – Severe Alzheimer’s disease